Determination and Control of Genotoxic Impurity in Vitamin E, Drug Substance

Authors

  • Rohidas Gilbile  Department of Chemistry, Pacific Academy of Higher Education and Research University, Udaipur, Rajasthan, India
  • Saleem Shaikh  Ullmann Laboratories, Five Star Shendra ,MIDC Aurangabad, Maharashtra State, India.
  • Ritu Vyas  Department of Chemistry, Pacific Academy of Higher Education and Research University, Udaipur, Rajasthan, India

Keywords:

P-toluenesulfonic acid; alpha-tocopherol; Reverse phase chromatography; Gradient elution. Vitamin E

Abstract

Vitamin E (alpha-tocopherol) is a lipid-soluble antioxidant. p-toluenesulfonic acid, used as reagent in the synthesis of alpha-tocopherol, has a sulphonate group, a well-known alerting function for genotoxic activity. Genotoxic impurities in pharmaceuticals at lower levels are of increasing concerns not only to pharmaceutical industries but also for the regulatory agencies due to their risks for human carcinogenesis and, thus, requiring manufacturers to pay extra attention for their analysis and control. Therefore, sensitive and sophisticated analytical methodologies are deemed necessary in order to be able to test and control genotoxic impurities in drug substances. This work describes a simple, accurate and sensitive reversed-phase liquid chromatography—UV method for determination of trace amount of p-toluenesulfonic acid in pharmaceutical materials. A gradient mobile phase consists of acetonitrile and 0.01M potassium dihydrogen orthophosphate in water adjusted pH 3.0 with 0.1% phosphoric acid. Chromatography was carried out at ambient temperature 25°C on a Waters HPLC column C18, 150 mm x 4.6 mm, 5?m. The detection was carried out using variable wavelength UV-Vis detector set at 222 nm. The compounds were eluted at a steady flow rate of 1.0 mL/min. P-toluenesulfonic acid retention time was about 6.0 min with an asymmetry factor of 1.0. A logarithmic calibration curve was obtained from 0.1 to 3 µg/mL (r > 0.9998). Within-day %RSD was 0.21 (n = 5, 0.002 mg/mL) and between-day %RSD was 0.35 Specificity/ selectivity experiments revealed the absence of interference, recovery from spiked samples was between 97.6–103.78 percent. The developed method was applied to the determination of p-toluenesulfonic acid in pharmaceutical drug substance and drug product.

References

  1. The European Medicines Agency EMEA], Committee for Medicinal Products for Human Use CHMP], Guidelines on the Limits of Genotoxic Impurities, CPMP/SWP/5199/02.
  2. The European Medicines Agency EMEA], Committee for Medicinal Products for Human Use CHMP], Questions and Answers on the CHMP Guideline on the Limits of Genotoxic Impurities, CPMP/SWP/431994/07.
  3. ICH Harmonized Tripartite Guideline, International Conference on Harmonization on Technical Requirements for Registration of Pharmaceuticals for Human Use, Q2A, Text on Validation of Analytical Procedures, Step 4 of the ICH process (1994) and Q2B, Validation of Analytical Procedures: Methodology, Step 4 of the ICH process, ICH Steering Committee (1996) International Conference on Harmonization, Geneva, Switzerland.
  4. Syntagon Newsletter, “A pragmatic approach to controlling potentially genotoxic impurities for phase-1” June 2009; Issue 2, www.syntagon.com/PGI.aspx.
  5. Glowienke S, Frieauff W, Allmendinger T, Martus H, Suter W, Mueller L. Mutat. Res. 581 (2005) 23.
  6. Muller L, et al. Regulatory Toxicology and Pharmacology. 2006; 44: 198-211.
  7. Kirkland D, Snodin D, “Setting limits for genotoxic impurities in drug substances: Threshold-based and pragmatic approaches” Int J Pharm Med, 2004; 18(4): 197-207.
  8. Questions and answers on the CHMP guideline on the limits of genotoxic impurities, Revision-1; EMEA/CHMP/SWP/43 1994/2007, CHMP safety working party: London, 26 June 2008.
  9. Muller L, Mauthe RJ, Riley CM, Andino MM, De Antonis D, Beels C et al., “A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity” Regul Toxicol Pharmacol, 2006; 44(3): 198-211, doi:10.10 16/j.yrtph.2005.12.001.
  10. US Food and Drug Administration, Guidance for Industry, Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches, Draft Guidance. Dec. 2008.
  11. Anhalt J.P, Brown S.D. High-performance liquid-chromatographic assay of aminoglycoside antibiotics in serum, Clin. Chem. 1978; 24: 1940-1947.
  12. Soltés L, Aminoglycoside antibiotics- two decades of their HPLC bioanalysis, Biomed. Chromatogr.1999; 13: 3-10.
  13. Hewitt W. L. Gentamicin: Toxicity in perspective, Postgrad. Med. J.1974; 50: 55-59
  14. Ghinami C, Giuliani V, Menarini A, Abballe F, Travaini S, Ladisa T, Electrochemical detection of p-toluenesulfonic acid or gentamicin according to the European Pharmacopoeia analytical method,  J. Chromatogr. A. 2007;1139: 53-56.
  15. USP 40 NF 35, United States Pharmacopoeia, 2017; 6703-6705.
  16. Guo M. X, L .Wrisley L , Maygoo E. Measurement of p-toluenesulfonic acid by reversed-phase high-performance liquid chromatography with mass spectrometry detection, Anal. Chim. Acta. 2006; 571:12-16.
  17. Keevil B.G, Lockhart S.J, Cooper D.P. Determination of p-toluenesulfonic acid in serum using liquid chromatography–tandem mass spectrometry and comparison with a fluorescence polarisation assay, J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2003; 794, 329-335.
  18. Barends D.M, Zwaan C.L, Hulshoff A. Micro-determination of p-toluenesulfonic acid in serum by high-performance liquid chromatography with ultraviolet detection  J. Chromatogr. B. 1981; 225: 417-426.
  19. Attema-de Jonge M.E, Bekkers J.M, Oudemans-van Straaten H.M, Sparidans R.W, Franssen E.J, Simple and sensitive method for quantification of low p-toluenesulfonic acid concentrations in human plasma using HPLC-MS/MS, J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2008;862: 257-262.
  20. Clarot I, Storme-Paris I, Chaminade P, Estevenon O, Nicolas A, Rieutord A, Simultaneous quantitation of p-toluenesulfonic acid and colistin sulphate by HPLC with evaporative light scattering detection, J. Pharm. Biomed. Anal. 2009;  50: 64-67.
  21. Megoulas N.C, Koupparis M.A, Development and validation of a novel HPLC/ELSD method for the direct determination of p-toluenesulfonic acid in pharmaceuticals, plasma, and urine, Anal. Bioanal. Chem. 2005; 382: 290-296.

Downloads

Published

2017-10-31

Issue

Section

Research Articles

How to Cite

[1]
Rohidas Gilbile, Saleem Shaikh, Ritu Vyas, " Determination and Control of Genotoxic Impurity in Vitamin E, Drug Substance , International Journal of Scientific Research in Science, Engineering and Technology(IJSRSET), Print ISSN : 2395-1990, Online ISSN : 2394-4099, Volume 3, Issue 6, pp.953-960, September-October-2017.